From the Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CAand the.
Division of Pediatric Gastroenterology, Hepatology & Nutrition, Lucille Packard Children's Hospital at Stanford, Stanford, CA.
J Pediatr Gastroenterol Nutr. 2022 Aug 1;75(2):196-201. doi: 10.1097/MPG.0000000000003499. Epub 2022 Jun 1.
Endoscopic retrograde cholangiopancreatography (ERCP) is increasingly utilized for management of biliary disorders in children and adolescents. Practice patterns surrounding cholangioscopy in pediatric patients, however, are largely uncharacterized.
We retrospectively analyzed all ERCPs in which cholangioscopy was performed on patients 18 and under at our tertiary care children's hospital from 2015 to 2020 using our institution's paper and electronic medical record system. Patient demographics, procedure indications, interventions, and associated adverse events were analyzed.
Over the study period, 307 ERCPs were performed on 282 patients at our children's hospital. Cholangioscopy was performed in 36 procedures (11.7%) using the SpyGlass cholangioscope (Boston Scientific). Antibiotics to cover biliary organisms were administered to all patients precholangioscopy. Mean patient age was 13.6 years (range 7-18 years). The 2 most common indications for cholangioscopy included electrohydraulic lithotripsy for biliary stone disease and evaluation of biliary stricture (with incidental finding of biliary web in 2 patients and retained suture material in 2 patients). Adverse events were less prevalent in patients who underwent cholangioscopy relative to those who underwent ERCP. 0/36 (0%) developed post-ERCP pancreatitis, one patient had self-limited melena (possible self-limited postsphincterotomy bleeding). Patient care was enhanced by cholangioscopy in 30/36 (83.3%) of these patients.
These data attest to the safety and clinical utility of cholangioscopy in children and adolescents. Cholangioscopy was performed in just over 11% of pediatric patients who underwent ERCP at our academic medical center-rates similar to those reported in adult patients. The radiation-sparing nature of cholangioscopy, coupled with these data supporting its safety, make it particularly appealing for use in children. Further multi-institution evaluation of the utility, safety, and range of indications for cholangioscopy in other practice settings would be of great interest and help guide endoscopic care.
内镜逆行胰胆管造影术(ERCP)越来越多地用于治疗儿童和青少年的胆道疾病。然而,儿科患者胆管镜检查的实践模式在很大程度上尚未确定。
我们使用机构的纸质和电子病历系统,回顾性分析了 2015 年至 2020 年在我们的三级儿童医院进行的所有胆管镜检查的 18 岁及以下患者的 ERCP。分析了患者的人口统计学特征、程序适应证、干预措施和相关不良事件。
在研究期间,我们儿童医院共进行了 307 例 ERCP,其中 282 例患者接受了胆管镜检查。使用 SpyGlass 胆管镜(波士顿科学公司)进行了 36 例胆管镜检查(11.7%)。所有患者在胆管镜检查前均接受了针对胆道生物的抗生素治疗。患者平均年龄为 13.6 岁(7-18 岁)。胆管镜检查的两个最常见适应证包括电液压碎石术治疗胆道结石病和评估胆道狭窄(在 2 例患者中发现胆管网,在 2 例患者中发现留置缝线)。与未行胆管镜检查的患者相比,行胆管镜检查的患者不良事件发生率较低。36 例患者中无 0/36(0%)发生 ERCP 后胰腺炎,1 例患者出现自限性黑便(可能为自限性括约肌切开后出血)。在 30/36(83.3%)患者中,胆管镜检查增强了患者的治疗效果。
这些数据证明了胆管镜检查在儿童和青少年中的安全性和临床实用性。在我们的学术医疗中心,胆管镜检查在接受 ERCP 的儿科患者中占比略高于 11%,与成人患者报告的比例相似。胆管镜检查具有放射防护的特点,再加上这些数据支持其安全性,使其特别适用于儿童。进一步在其他实践环境中进行多机构评估胆管镜检查的实用性、安全性和适应证范围,将非常有意义,并有助于指导内镜治疗。